ImmunityBio, bladder cancer
FDA OKs First IL-15 Receptor Agonist for Early Bladder Cancer
A first-in-class interleukin (IL)-15 receptor agonist, the drug is specifically approved in combination with BCG for adults with BCG-unresponsive NMIBC with carcinoma in situ with or without papillary tumors.
U.S. FDA approves ImmunityBio's bladder cancer therapy
The U.S. health regulator on Monday approved ImmunityBio's combination therapy to treat a type of bladder cancer, marking an end to the company's efforts to bring its therapy to the market.
ImmunityBio: FDA Approval Gets Ball Rolling Towards Next Set Of Indications
ImmunityBio finally received FDA approval for its drug ANKTIVA for the treatment of patients with BCG-unresponsive NMIBC with CIS. Read more on IBRX stock here.
FDA approves immunotherapy drug combo for non-muscle invasive bladder cancer
The U.S. Food and Drug Administration (FDA) has approved the immunotherapy-boosting drug N-803, which is marketed under the brand name Anktiva, to be used in combination with the immunotherapy Bacillus Calmette-Guerin (BCG) for the treatment of patients with BCG-unresponsive non–muscle-invasive bladder cancer.
Day One Biopharmaceuticals Drug Tovorafenib Gets FDA Accelerated Approval
By Josh Beckerman Day One Biopharmaceuticals' drug tovorafenib, or Ojemda, received accelerated approval from the U.S. Food and Drug Administration
ImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer Battle
ImmunityBio has financial resources for the short-term, but long-term financial health remains uncertain. Click here to read my IBRX update.
FDA Approves New Bladder Cancer Drug
The first-in-class agent is approved alongside bacillus Calmette-Guérin to treat certain non–muscle-invasive bladder cancers that do not respond to bacillus Calmette-Guérin alone.
FDA approves bladder cancer treatment by Culver City company
The Food and Drug Administration on Monday approved Culver City-based ImmunityBio's treatment for a type of bladder cancer.
ImmunityBio stock jumps as FDA clears bladder cancer therapy
Shares of ImmunityBio (IBRX) surged 33% premarket after FDA clearance of its combination therapy for bladder cancer treatment.
FDA recommends Heimlich maneuver over use of unapproved anti-choking devices
People should rely on the well-established Heimlich maneuver to save a choking victim, rather than newfangled "anti-choking" ...
WBJournal5h
FDA issues most serious recall against Boston Scientific’s blood vessel blocking device
The U.S. Food and Drug Administration has issued a recall of Boston Scientific’s Obsidio conformable embolic medical device ...
MassDevice1h
FDA clears Sail Fusion’s BowTie Sacroiliac Fusion System
Sail Fusion today announced it received FDA 510 (k) clearance for its BowTie Sacroiliac Fusion System.
This Pharma Co. Kicks Off FDA Approval Process For CBD-Based Treatment Of Chronic Pain
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced on Monday that it has submitted its letter of ...
Daily Express US on MSN3h
Popular cooking oil recalled in California stores as FDA warns of huge hazard
Over 2,000 cases of Primal Kitchen's avocado oil have been recalled due to a packaging issue making the glass bottles prone ...
Day One wins FDA nod for brain cancer therapy, Ojemda
The FDA approves Day One Biopharmaceuticals' (DAWN) lead asset tovorafenib for pediatric low-grade glioma, a ...
Pharm Exec1h
FDA Approves Novartis' Lutathera for Pediatric Patients with Gastroenteropancreatic Neuroendocrine Tumors
Lutathera is the first FDA-approved treatment for younger patients with somatostatin receptor-positive gastroenteropancreatic ...
BioPharma Dive4h
FDA rejects Abeona cell therapy, asks for more manufacturing data
The complete response letter for Abeona’s treatment is one of several manufacturing setbacks for cell and gene therapy developers in recent years.